From: Changing etiologies and outcome of liver failure in Southwest China
 | Sex (%) |  | Age |  | |
---|---|---|---|---|---|
 | Male | Female | P value | (years) | P value |
All cases (n = 3171) | 82.18 % | 17.82 % |  | 41.9 ± 12.4 (0.5–83) |  |
Clinical types | Â | Â | Â | Â | Â |
 ALF (n = 75)a | 56.00 % | 44.00 % | 0.000 | 33.7 ± 17.5 (0.5–76) | 0.000 |
 SALF (n = 174)a | 47.70 % | 52.30 % | 0.000 | 37.4 ± 17.4 (3–79) | 0.000 |
 ACLF (n = 2922) | 84.90 % | 15.10 % |  | 42.4 ± 11.7 (8–83) |  |
HBV (n = 2906) | 85.40 % | 14.60 % |  | 42.0 ± 11.7 (8–83) |  |
non-HBV (n = 265)b | 47.20 % | 52.80 % | 0.000 | 40.7 ± 18.4 (0.5–79) | 0.258 |
ALD (n = 573) | 98.40 % | 1.60 % | 0.000 | 46.0 ± 10.3 (21–77) | 0.000 |
DILI (n = 171) | 69.60 % | 30.40 % | 0.000 | 41.7 ± 14.7 (4–75) | 0.658 |
 Antituberculosis (n = 107) | 85.00 % | 15.00 % |  | 39.1 ± 12.2 (16–72) |  |
 Chinese herbs (n = 41)& | 36.60 % | 63.40 % | 0.000 | 48.6 ± 14.9 (11–72) | 0.001 |
HAV (n = 27) | 85.20 % | 14.80 % | 0.570 | 36.4 ± 15.2 (3–75) | 0.033 |
HEV (n = 102) | 89.20 % | 10.80 % | 0.167 | 42.2 ± 13.9 (17–81) | 0.419 |
HDV (n = 74) | 86.50 % | 13.50 % | 0.478 | 43.8 ± 11.7 (14–68) | 0.084 |
HCV (n = 23) | 87.00 % | 13.00 % | 0.563 | 38.4 ± 10.4 (24–64) | 0.116 |
Withdrawal (n = 164) | 84.30 % | 15.70 % | 0.506 | 42.5 ± 10.4 (20–71) | 0.363 |
Resistance (n = 37) | 83.80 % | 16.20 % | 0.461 | 42.4 ± 9.8 (13–63) | 0.400 |
Steroids use (n = 63) | 74.60 % | 25.40 % | 0.018 | 46.4 ± 12.5 (22–69) | 0.005 |
Indeterminate (n = 85)b | 37.60 % | 62.40 % | 0.000 | 38.8 ± 20.0 (0.5–79) | 0.015 |